Geron (NASDAQ:GERN – Get Rating) had its price target boosted by Wedbush from $5.00 to $6.00 in a report issued on Wednesday, The Fly reports. Wedbush currently has an outperform rating on the biopharmaceutical company’s stock.
Separately, StockNews.com raised shares of Geron to a sell rating in a report on Tuesday, December 27th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of Moderate Buy and an average price target of $5.00.
Geron Price Performance
NASDAQ:GERN opened at $3.19 on Wednesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.68 and a quick ratio of 2.68. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -8.86 and a beta of 0.76. The company has a 50 day moving average price of $2.25 and a 200-day moving average price of $2.19. Geron has a 1-year low of $0.99 and a 1-year high of $3.84.
Institutional Investors Weigh In On Geron
A number of institutional investors have recently added to or reduced their stakes in GERN. OmniStar Financial Group Inc. acquired a new stake in Geron in the 3rd quarter valued at $25,000. Merit Financial Group LLC acquired a new stake in Geron in the 2nd quarter valued at $27,000. Elmwood Wealth Management Inc. grew its stake in Geron by 44.6% in the 2nd quarter. Elmwood Wealth Management Inc. now owns 19,450 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 6,000 shares during the period. Lido Advisors LLC acquired a new stake in Geron during the 3rd quarter worth $35,000. Finally, High Net Worth Advisory Group LLC acquired a new stake in Geron during the 1st quarter worth $35,000. Institutional investors and hedge funds own 49.75% of the company’s stock.
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.
- Get a free copy of the StockNews.com research report on Geron (GERN)
- GE HealthCare Technologies Soars As GE Legacy Business Plummets
- Keep These 3 Dividend Contenders on the 2023 Watch List
- 3 Energy Stock Winners With More in the Tank
- Can Amazon Lead Consumer Stocks To A Big Rally In 2023?
- Will Canada Goose Stock Fly Higher for the Winter?
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.